Name

China Shineway Pharmaceutical

Legal name

China Shineway Pharmaceutical Group Limited

Website

https://shineway.com.hk

Company type

Public

Founded year

1984

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Traditional Chinese Medicine / Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Modern Chinese medicine
• TCM injections
• TCM formula granules
• Pharmaceutical manufacturing
• Soft capsule formulations

Headquarters

HQ city

Wan Chai

HQ country

Hong Kong SAR China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Modern Chinese Medicine Products Sales: Primary revenue from manufacturing and sales of modern Chinese medicines in three major dosage forms: injections, soft capsules and granules. The Group covers the whole value chain including cultivation, scientific research, extraction, production, and marketing.
2. TCM Formula Granules: Sales of TCM formula granules through medical insurance system with price negotiations. Constituted about 20.9% of total turnover in 2020 with sales increasing 10.8% year-over-year.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

China Shineway Pharmaceutical is a large-scale manufacturer of modern Chinese medicine producing drugs in three major dosage forms: injections, soft capsules, and granules. The Group covers the entire value chain from cultivation of raw herbal materials, scientific research, extraction, production, and marketing, with a product portfolio that includes National Essential Drugs, National Medical Insurance Drugs, cardiovascular medications, antiviral products, pediatric medications, and proprietary TCM formula granules.

Product overview

China Shineway Pharmaceutical Group is a large-scale comprehensive enterprise primarily engaged in modern Chinese medicine business. The company operates as a professional manufacturer of modern Chinese medicine in three major dosage forms: injections, soft capsules, and granules. Their product portfolio includes National Essential Drugs (Qingkailing Injection, Shenmai Injection, Danshen Injection, Bupleurum Injection, Huoxiang Zhengqi Soft Capsules, Banlangen Granules), National Medical Insurance Drugs (Chaihu Injection, Shuanghuanglian Injection), cardiovascular medications (Shuxiening Injection, Guanxinning Injection, Safflower Injection), and TCM Formula Granules—a core product representing the highest technical merit of modern TCM. The Group covers the entire value chain including cultivation, scientific research, extraction, production, and marketing of Chinese medicine. Their sales network covers more than 30 provinces, municipalities, and autonomous regions nationwide, with products exported internationally.

Differentiator

Problem solved

Functional benefit

Products and services

• Qingkailing Injection
• Shenmai Injection
• Danshen Injection
• Bupleurum Injection
• Huoxiang Zhengqi Soft Capsules
• Banlangen Granules
• Qingkailing Soft Capsules
• TCM Formula Granules
• Shuxiening Injection
• Guanxinning Injection
• Dengzhanhuasu Injection
• Safflower Injection
• Wufu Xinnaoqing Soft Capsules
• Xiesaitong Dripping Pills
• Chaihu Injection
• Shuanghuanglian Injection
• Yiguan Jian Granule
• Sailuotong Capsule
• JC Soft Capsule
• Yi Gong San Granules
• BEISI (Ibuprofen Oral Liquid)

Quantifiable outcome

• 2023 full-year sales exceeded RMB 4.5 billion, up 14.3% year-over-year
• +4 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Tsinghua UniversitycoreStrategic or Co-development PartnerLong-term scientific research partnership for traditional Chinese medicine research and development. Jointly completed National Science and Technology Progress Award-winning project on Comprehensive Quality Control of Traditional Chinese Medicine Injections.
• Peking UniversitycoreStrategic or Co-development PartnerLong-term scientific research partnership for traditional Chinese medicine research and development.
• China Academy of Chinese Medical SciencescoreStrategic or Co-development PartnerLong-term scientific research partnership for traditional Chinese medicine research and development and innovation.

Scale indicators9 records

Recent moves7 records

Direct peers

• China Traditional Chinese Medicine Holdings Limited: Hong Kong-listed manufacturer of modern TCM formulations in granules, injections, and capsules, with overlapping dosage forms, hospital channel presence, and R&D in TCM modernization—directly comparable in business model and product format.
• Pien Tze Huang Pharmaceutical Co., Ltd. Specialized branded TCM manufacturer with proprietary classic prescriptions and national hospital/pharmacy reach; comparable in branded TCM positioning, premium pricing, and National Essential Drug listings.
• Beijing Tongrentang Co., Ltd. Iconic Chinese TCM producer with classic prescription-based products and broad hospital/pharmacy distribution; comparable as a branded TCM manufacturer with national essential drug listings and a long heritage franchise.
• Yunnan Baiyao Group Co., Ltd. Leading China-based TCM and consumer health manufacturer with branded proprietary formulations sold through hospital and pharmacy channels; comparable in branded TCM focus, therapeutic reach, and large-scale manufacturing.
• China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Major state-backed TCM and OTC pharmaceutical manufacturer with national distribution; comparable in branded TCM, OTC, and essential drug exposure across hospital and retail channels.
• Conba Pharmaceutical Co., Ltd. Large Chinese TCM manufacturer with focus on modernized dosage forms and hospital channel sales; comparable in product format mix and reliance on National Medical Insurance reimbursement.
• Tasly Pharmaceutical Group Co., Ltd. Modern TCM specialist with proprietary compound formulations (e.g., cardiovascular TCM) and injection/granule formats; comparable in modernized TCM R&D and cardiovascular therapeutic focus.

Broad incumbents

• Guangzhou Pharmaceutical Holdings Limited: State-owned pharma group with major TCM brands (e.g., Wanglaoji/Caiqin) and OTC franchise; comparable as a large incumbent operating in branded TCM and consumer health.
• Jiangsu Hengrui Pharmaceuticals Co., Ltd. China's largest innovative drug developer with a strong hospital channel; comparable as a large listed Chinese pharmaceutical player with similar hospital access and regulatory navigation, though primarily focused on Western innovative medicines.
• Shanghai Pharmaceuticals Holding Co., Ltd. One of China's largest pharmaceutical conglomerates spanning innovative drugs, generics, TCM, and distribution; comparable as a broad incumbent in the same therapeutic and distribution space, though much larger and more diversified.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/china-shineway-pharmaceutical-group-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about China Shineway Pharmaceutical